Psoriasis pathogenesis and the development of novel targeted immune therapies.

Hawkes, Jason E; Chan, Tom C; Krueger, James G

Hawkes, Jason E; Chan, Tom C; Krueger, James G.

Afiliación

Hawkes JE; Laboratory for Investigative Dermatology, Rockefeller University, New York, NY.
Chan TC; Laboratory for Investigative Dermatology, Rockefeller University, New York, NY.
Krueger JG; Laboratory for Investigative Dermatology, Rockefeller University, New York, NY. Electronic address: kruegej@rockefeller.edu.

J Allergy Clin Immunol ; 140(3): 645-653, 2017 Sep.

Article en En | MEDLINE | ID: mdl-28887948

Asunto(s)

Psoriasis/inmunología; Animales; Humanos; Interleucina-17/inmunología; Psoriasis/tratamiento farmacológico; Linfocitos T/inmunología; Factor de Necrosis Tumoral alfa/antagonistas & inhibidores

Palabras clave

IL-17; IL-23; Psoriasis; autoantigens; brodalumab; ixekizumab; psoriatic arthritis; secukinumab; tildrakizumab, guselkumab, and risankizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Psoriasis Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Allergy Clin Immunol Año: 2017 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google